Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy Journal Article

  


Authors: Eisenhauer, E. L.; Tew, W. P.; Levine, D. A.; Lichtman, S. M.; Brown, C. L.; Aghajanian, C.; Huh, J.; Barakat, R. R.; Chi, D. S.
Article Title: Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy
Abstract: Objective.: Recent reports have suggested that only half of women age ≥ 65 with advanced ovarian cancer are treated with platinum-based chemotherapy. The objective of this study was to compare the response to platinum-taxane chemotherapy and subsequent outcomes between patients older and younger than 65 years of age with stages IIIC-IV epithelial ovarian cancer (EOC). Patients and methods.: A cohort study was performed of all patients with stages IIIC-IV EOC who had their primary surgery at our institution from 1998 to 2004 and subsequently began platinum-taxane chemotherapy. Main outcomes were response to primary chemotherapy, platinum resistance and progression-free (PFS) and overall survival (OS). Results.: A total of 292 patients began primary platinum-taxane therapy after surgery and comprised our study group. Of these, 108 (37%) were ≥ 65 years old and 184 (63%) were < 65. Stage of disease, optimal cytoreduction rate, number of chemotherapy cycles and chemotherapy regimen alterations were similar between groups. Patients ≥ 65 achieved a clinical complete response with a similar frequency to those < 65 (70% vs. 79%) and had similar rates of platinum sensitivity at 6 months (61% vs. 65%). Patients ≥ 65 had equivalent PFS (P = 0.99) and OS (P = 0.36) to those < 65. Age ≥ 65 years was not independently associated with impaired survival. Conclusions.: Patients ≥ 65 years of age demonstrated similar rates of initial response, platinum resistance, PFS and OS to younger patients. Elderly women who can tolerate primary cytoreductive surgery should receive combination platinum-taxane chemotherapy. © 2007 Elsevier Inc. All rights reserved.
Keywords: adult; cancer survival; treatment outcome; treatment response; aged; aged, 80 and over; disease-free survival; middle aged; major clinical study; drug tolerability; cisplatin; area under the curve; cancer growth; drug dose reduction; drug efficacy; paclitaxel; combined modality therapy; chemotherapy; cancer staging; neoplasm staging; ovarian cancer; ovarian neoplasms; carboplatin; ovary cancer; cohort studies; bone marrow suppression; thrombocytopenia; antineoplastic combined chemotherapy protocols; peripheral neuropathy; cohort analysis; combination chemotherapy; age factors; docetaxel; rash; taxoids; platinum complex; taxane derivative; organoplatinum compounds; drug sensitivity; elderly care; hearing loss; electrolyte disturbance; elderly patients; platinum-taxane chemotherapy
Journal Title: Gynecologic Oncology
Volume: 106
Issue: 2
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2007-08-01
Start Page: 381
End Page: 387
Language: English
DOI: 10.1016/j.ygyno.2007.04.012
PUBMED: 17509673
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-34447628517&partnerID=40&md5=94e8a1fe5274a502211a94f781cfdc6d
Notes: --- - "Cited By (since 1996): 19" - "Export Date: 17 November 2011" - "CODEN: GYNOA" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Richard R Barakat
    629 Barakat
  2. Carol Brown
    167 Brown
  3. Dennis S Chi
    707 Chi
  4. Douglas A Levine
    380 Levine
  5. Eric Eisenhauer
    36 Eisenhauer
  6. Stuart Lichtman
    228 Lichtman
  7. Jae Nyung Ward
    19 Ward
  8. Carol A Aghajanian
    609 Aghajanian
  9. William P Tew
    246 Tew
Related MSK Work